News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zydus Cadila Seeks Big Pharma Tie-Up to Launch Diabetes Drug Overseas



6/6/2013 7:32:34 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Zydus Cadila today said it is looking for partnership to market its new chemical entity (NCE) Lipaglyn, to be used for treating a type of diabetes in developed and developing markets. "Lipaglyn is the first glitazar to be approved in the world and the first NCE discovered and developed indigenously by an Indian pharma company. The new drug is expected to be launched in Q3 of this fiscal in the country," Zydus Cadila Chairman and Manging Director Pankaj Patel told reporters. The company has spent USD 250 million in developing Lipaglyn and aims to spend another USD 150-200 million to launch the drug in overseas markets in next 3-5 years period, Patel said, adding that the company is looking for marketing partnerships.

Help employers find you! Check out all the jobs and post your resume.

Read at Money Control
Read at DNA India
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES